Here are four things to know.
1. The FDA approved Bavencio to treat advanced or metastatic bladder cancer in patients whose disease still progresses after chemotherapy.
2. New York City-based Pfizer developed the drug with Darmstadt, Germany-based Merck. As part of the accelerated approval, the drugmakers must conduct another clinical trial to confirm the drug’s efficacy for this treatment indication.
3. The drug will cost about $13,000 a month for the average bladder cancer patient, according to German Merck.
4. The decision comes just two months after Bavencio received FDA approval to treat a rare form of skin cancer.
More articles on supply chain:
WHO calls for global drug price transparency
Patients barter for costly medications on Facebook
PhRMA issues new membership criteria, boots more than 20 drugmakers
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
